What's New

4523

Eisai Co., Ltd.

The Media/Investor Conference

8252

Marui Group., Ltd.

MARUI IR DAY

Managing Executive Officer, President and Representative Director, Epos Card Co., Ltd. Yoshionori Saito
8766

Tokio Marine Holdings, Inc.

Tokio Marine Group Business Strategy

President and Group CEO Satoru Komiya
8630

Sompo Holdings, Inc.

New Medium-term Management Plan (FY2021-2023)

Kengo SAKURADA Group CEO
4503

Astellas Pharma Inc.

CSP2021(CSP: Corporate Strategic Plan)

Representative Director, President and Chief Executive Officer (CEO) Kenji Yasukawa, Ph.D.
7013

IHI Corporation

Financial Results for FY2020 (IFRS) (for the year ended March 31,2021)

President and CEO Hiroshi Ide
8252

Marui Group., Ltd.

2021年3月期決算説明会

代表取締役社長 青井 浩
4523

Eisai Co., Ltd.

FY2020 (Fiscal Year Ending March 31, 2021) Financial Results Presentation

Representative Corporate Officer and CEO Haruo Naito
8604

Nomura Holdings, Inc.

Investor Day

Group CEO
Kentaro Okuda
4502

Takeda Pharmaceutical Company Limited

FY2020 Q4 Earnings Announcement #2

President & Chief Executive Officer
Christophe Weber
4502

Takeda Pharmaceutical Company Limited

FY2020 Q4 Earnings Announcement #1

President & Chief Executive Officer
Christophe Weber
4502

Takeda Pharmaceutical Company Limited

FY2020 Earnings Media Presentation

President and CEO
Christophe Weber
8604

Nomura Holdings, Inc.

Fourth Quarter and Full Year Operating Results for Fiscal Year Ended March 2021

CFO
Takumi Kitamura
4503

Astellas Pharma Inc.

FY2020 FINANCIAL RESULTS ENDED MARCH 31, 2021

President and CEO Kenji Yasukawa, Ph.D.
4502

Takeda Pharmaceutical Company Limited

WAVE 1 PIPELINE MARKET OPPORTUNITY CALL (PART 2)

President & CEO Takeda
Christophe Weber
4523

Eisai Co., Ltd.

Information Meeting

Representative Corporate Officer and CEO Haruo Naito
4503

Astellas Pharma Inc.

Rx+ Day

Executive Vice President, Chief Strategy Officer and Chief Financial Officer
Naoki Okamura
4502

Takeda Pharmaceutical Company Limited

Growth and Emerging Markets Strategic Update Call

President,Growth & Emerging Markets
Ricardo Marek
4502

Takeda Pharmaceutical Company Limited

Investors and Analysts on Takeda’s Japan Oncology Business and its oncology products and disease in Japan

Global Oncology Business Unit Head of Japan Oncology Business Unit
Taka Horii
7013

IHI Corporation

Financial Results for Third Quarter FY2020 (for the year ending March 31, 2021)

Finance and Accounting Division, General Manager Seiji Maruyama
4502

Takeda Pharmaceutical Company Limited

Conference Call for the Announcement of 3rd Quarter Financial Results for Fiscal Year 2020

President and Chief Executive Officer
Christophe Weber
4204

SEKISUI CHEMICAL CO., LTD.

Presentation of Financial Results for the 3Q of FY2020

Director, Senior Managing Executive Officer, Head of Business Strategy Dept. Futoshi Kamiwaki
4503

Astellas Pharma Inc.

Q3/FY2020 FINANCIAL RESULTS ENDED DECEMBER 31, 2020

Executive Vice President, Chief Strategy Officer and Chief Financial Officer Naoki Okamura
4503

Astellas Pharma Inc.

R&D Meeting

President & CEO Kenji Yasukawa Ph.D.
4502

Takeda Pharmaceutical Company Limited

Wave 1 Pipeline Market Opportunity Call

President & CEO
Christophe Weber
8604

Nomura Holdings

Nomura Investment Forum 2020

Group CEO Kentaro Okuda
8766

Tokio Marine Holdings, Inc.

Investor Day - Closing Remarks -

Group CEO Group CCO Satoru Komiya
8766

Tokio Marine Holdings, Inc.

Investor Day - Financial Business Strategy -

Group CIO Yoshinari Endo
8766

Tokio Marine Holdings, Inc.

Investor Day - International Business Strategy -

Co-Head of International Business Akira Harashima
8766

Tokio Marine Holdings, Inc.

Investor Day - Domestic Business Strategy -

President & CEO Tokio Marine & Nichido Shinichi Hirose
8766

Tokio Marine Holdings, Inc.

Investor Day - Group Business Strategy -

Group CEO Group CCO Satoru Komiya
8630

Sompo Holdings, Inc.

Progress of Mid-Term Management Plan and Principles of Next Mid-Term Management Plan

President(Group CEO) Kengo Sakurada
8252

Marui Group., Ltd.

2020年3月期第2四半期決算説明会

代表取締役社長 青井 浩
4536

Santen Pharmaceutical Co., Ltd.

Q2 FY2020 Results

President & Chief Executive Officer Shigeo Taniuchi
4204

SEKISUI CHEMICAL CO., LTD.

Presentation of Financial Results and Progress under Management Plan for the 2nd Quarter FY2020

4503

Astellas Pharma Inc.

Q2/FY2020 FINANCIAL RESULTS ENDED SEPTEMBER 30, 2020

President and CEO Kenji Yasukawa, Ph.D.
4502

Takeda Pharmaceutical Company Limited

Conference Call for the Announcement of 2nd Quarter Financial Results for Fiscal Year 2020

President and Chief Executive Officer
Christophe Weber
4502

Takeda Pharmaceutical Company Limited

Conference Call for the Announcement of 2nd Quarter Financial Results for Fiscal Year 2020

President and Chief Executive Officer
Christophe Weber
4502

Takeda Pharmaceutical Company Limited

FY2020 H1 Earnings Media Presentation

President and Chief Executive Officer
Christophe Weber
4503

Astellas Pharma Inc.

Q1/FY2020 FINANCIAL RESULTS ENDED JUNE 30, 2020

Representative Director, Corporate Executive Vice President, Chief Strategy Officer and Chief Financial Officer Naoki Okamura
4204

SEKISUI CHEMICAL CO., LTD.

Presentation of Financial Results for the 1st Quarter of FY2020

4502

Takeda Pharmaceutical Company Limited

Conference Call for the Announcement of 1st Quarter Financial Results for Fiscal Year 2020

President and Chief Executive Officer
Christophe Weber
4502

Takeda Pharmaceutical Company Limited

Conference Call for the Announcement of 1st Quarter Financial Results for Fiscal Year 2020

President and Chief Executive Officer
Christophe Weber
8252

Marui Group., Ltd.

MARUI IR DAY 中期経営計画進捗説明会

上席執行役員㈱丸井 取締役社長
青木 正久
8252

Marui Group., Ltd.

Financial Results Briefing for the Fiscal Year Ended March 31, 2020 and Future Outlook

President and Representative Director, MARUI GROUP CO., LTD. Hiroshi Aoi
8630

Sompo Holdings, Inc.

Progress of Mid-Term Management Plan

President(Group CEO) Kengo Sakurada
8766

Tokio Marine Holdings, Inc.

Tokio Marine Group Business Strategy

President and Group CEO Satoru Komiya
4204

SEKISUI CHEMICAL CO., LTD.

Long-term Vision and Medium-term Management Plan Presentation

4503

Astellas Pharma Inc.

FY2019 FINANCIAL RESULTS ENDED MARCH 31, 2020

President and CEO Kenji Yasukawa, Ph.D.
4536

Santen Pharmaceutical Co., Ltd.

Financial Disclosure Meeting FY2019 Business Highlights FY2020 Forecast

President & Chief Executive Officer Shigeo Taniuchi
3659

NEXON Co., Ltd.

Q4 2019 Earnings Presentation

President and Chief Executive Officer Owen Mahoney
4503

Astellas Pharma Inc.

Q3/FY2019 financial Results ended December 31, 2019

Representative Director, Corporate Executive Vice President, Chief Strategy Officer and Chief Financial Officer Naoki Okamura
8252

Marui Group., Ltd.

MARUI IR DAY 2019. 12

Hiroshi Aoi President and Representative Director, MARUI GROUP CO., LTD.
4503

Astellas Pharma Inc.

R&D Meeting

President and Chief Executive Officer Kenji Yasukawa, Ph.D.
4503

Astellas Pharma Inc.

ACQUISITION OF AUDENTES

Representative Director, Corporate Executive Vice President, Chief Strategy Officer and Chief Financial Officer Naoki Okamura
8630

Sompo Holdings, Inc.

Progress of Mid-term Management Plan

President(Group CEO) Kengo Sakurada
8766

Tokio Marine Holdings, Inc.

Tokio Marine Group Business Strategy

President and Group CEO Satoru Komiya
8252

Marui Group.Ltd.

Six Months Ended September 30 , 2019 Financial Results and Future Developments

Hiroshi Aoi President and Representative Director, MARUI GROUP CO., LTD.
4503

Astellas Pharma Inc.

Q2/FY2019 FINANCIAL RESULTS ENDED SEPTEMBER 30, 2019

President and CEO Kenji Yasukawa, Ph.D.
4507

SHIONOGI & CO., LTD.

3rdQuarter of Fiscal 2018 Financial Results Conference Call

Kohji Hanasaki, Ph.D. Senior Executive Officer, Senior Vice President, Finance & Accounting Department
8252

MARUI GROUP CO., LTD.

MARUI IR DAY 2018

Hiroshi Aoi President and Representative Director, Representative Executive Officer
8766

Tokio Marine Holdings, Inc.

Mid-Term Business Plan "To Be a Good Company 2020" FY2018 Business Plan Update

President and Group CEO Tsuyoshi Nagano
4536

Santen Pharmaceutical Co., Ltd.

Investor Meeting on Q2 FY2018 Results

President & Chief Operating Officer (COO) Shigeo Taniuchi

Precautions in use

Nomura IR assumes no responsibility for correctness, validity or any other nature of the contents on this server.
No act such as alteration, modification or addition to the contents is permitted.
Since the contents on this server are not intended to solicit investment, our company has no liability for any trouble related to investment made by any audience based on the contents of this site. Investors are required to decide at their own discretion.
Nomura IR assumes no responsibility for correctness, validity or any other nature of information, including its format and details, obtained from any site linked from our site.